XML 68 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
License Agreements - Novartis (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 110 Months Ended
Apr. 30, 2016
USD ($)
Jan. 31, 2010
USD ($)
Dec. 31, 2009
USD ($)
Nov. 30, 2009
USD ($)
item
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2010
USD ($)
Dec. 31, 2018
USD ($)
License agreements                                            
Revenues         $ 528,402 $ 449,683 $ 521,516 $ 382,282 $ 444,156 $ 381,534 $ 326,444 $ 384,082 $ 1,881,883                  
Europe                                            
License agreements                                            
Revenues                         79,900 $ 66,900 $ 29,600              
U.S.                                            
License agreements                                            
Revenues                         1,800,000 1,500,000 1,100,000              
JAKAFI                                            
License agreements                                            
Revenues                         1,386,964 1,133,392 852,816              
Novartis                                            
License agreements                                            
Upfront and immediate milestone payment to be received under license agreement       $ 210,000                                    
Upfront payment received under license agreement     $ 150,000                                      
Immediate milestone payment received under license agreement   $ 60,000                                        
Revenues                         60,000 65,000 45,000              
Number of deliverables under license agreement | item       2                                    
Reimbursable costs recorded as deferred revenue     $ 10,900                                      
Reimbursable costs included in accounts receivable         700       1,600       700 1,600               $ 700
Research and development expenses reimbursed                         3,200 3,000 700              
Product royalties in accounts receivable         55,400       47,700       55,400 47,700               55,400
Novartis | Pre-specified Events | Maximum                                            
License agreements                                            
Upfront and immediate milestone payment to be received under license agreement       $ 1,200,000                                    
Novartis | Development Milestones                                            
License agreements                                            
Amount recognized and received for the achievement of a predefined milestone                                           132,000
Novartis | Development Milestones | Phase III                                            
License agreements                                            
Amount recognized and received for the achievement of a predefined milestone                                         $ 50,000  
Novartis | Development Milestones | Maximum                                            
License agreements                                            
Upfront and immediate milestone payment to be received under license agreement       174,000                                    
Novartis | Regulatory Milestones                                            
License agreements                                            
Amount recognized and received for the achievement of a predefined milestone                                           215,000
Novartis | Regulatory Milestones | Maximum                                            
License agreements                                            
Upfront and immediate milestone payment to be received under license agreement       495,000                                    
Novartis | Commercialization Milestones                                            
License agreements                                            
Amount recognized and received for the achievement of a predefined milestone                                           120,000
Novartis | Commercialization Milestones | Maximum                                            
License agreements                                            
Upfront and immediate milestone payment to be received under license agreement       $ 500,000                                    
Novartis | LY3009104 | Development Milestones                                            
License agreements                                            
Amount recognized and received for the achievement of a predefined milestone                               $ 5,000 $ 7,000 $ 25,000   $ 15,000    
Novartis | GVHD | Development Milestones | Phase III                                            
License agreements                                            
Amount recognized and received for the achievement of a predefined milestone                           25,000                
Novartis | GVHD | Development and Regulatory Milestones | Maximum                                            
License agreements                                            
Upfront and immediate milestone payment to be received under license agreement $ 75,000                                          
Novartis | GVHD | Development and Commercialization Milestones                                            
License agreements                                            
Amount recognized and received for the achievement of a predefined milestone                             5,000              
Novartis | JAKAFI | U.S.                                            
License agreements                                            
Revenues                         63,000 50,500 36,800              
Royalties payable         $ 18,600       $ 14,800       18,600 14,800               $ 18,600
Novartis | JAKAFI | Regulatory Milestones | U.S.                                            
License agreements                                            
Amount recognized and received for the achievement of a predefined milestone                                       $ 10,000    
Novartis | JAKAVI                                            
License agreements                                            
Revenues                         $ 194,700 151,700 110,700              
Novartis | JAKAVI | Minimum                                            
License agreements                                            
Royalty payments on future global net sales (as a percent)                         12.00%                  
Novartis | JAKAVI | Maximum                                            
License agreements                                            
Royalty payments on future global net sales (as a percent)                         14.00%                  
Novartis | JAKAVI | Regulatory Milestones | Europe                                            
License agreements                                            
Amount recognized and received for the achievement of a predefined milestone                             $ 40,000 25,000 60,000   $ 40,000      
Novartis | JAKAVI | Regulatory Milestones | JAPAN                                            
License agreements                                            
Amount recognized and received for the achievement of a predefined milestone                               15,000 $ 25,000          
Novartis | JAKAVI | Commercialization Milestones                                            
License agreements                                            
Amount recognized and received for the achievement of a predefined milestone                         $ 60,000 40,000   20,000            
Revenues                         $ 900,000 $ 600,000   $ 300,000